 |
|
| Date | Title | | | 04/26/12 | InterMune Reports First Quarter 2012 Financial Results And Business Highlights| BRISBANE, Calif., April 26, 2012 /PRNewswire via COMTEX/ --InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the first quarter ended March 31, 2012. InterMune also highlighted its recent clinical development and business activities.
InterMune reported product revenue in the first quarter of 2012 of $8.9 million, consisting of approximately $4.9 million from sales of Esbriet® (pirfenidone) in Europe, and Actimmune® (gamma interferon-1b) revenue of approximately $4.1 mi... |
|  | | 04/19/12 | InterMune To Release First Quarter Financial Results On April 26| BRISBANE, Calif., April 19, 2012 /PRNewswire via COMTEX/ --InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2012 financial results at the close of the U.S. markets on Thursday, April 26, 2012. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.
Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21589296.... |
| | | 04/05/12 | France's Transparency Commission (CT) Issues Favorable Opinion for Reimbursement of Esbriet® (pirfenidone)| -- InterMune expresses confidence in ASCEND Phase 3 study outcome; updates timeline --
-- Company to conduct conference call and webcast at 4:30 p.m. EDT today --
BRISBANE, Calif., April 5, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that the Transparency Commission (CT: Commission de Transparence) of the French National Health Authority (HAS: Haute Autorite de Sante) has issued a favorable opinion for the reimbursement of Esbriet® (pirfenidone) by French National He... |
| | | 03/27/12 | InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors|
BRISBANE, Calif., March 27, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin Pharmaceutical, Inc., and Frank Verwiel, M.D., President and Chief Executive Officer of Aptalis Pharma, have been appointed to InterMune's Board of Directors.
"We are very pleased to welcome Mr. Bienaime and Dr. Verwiel as directors of InterMune. They bring to our board extensive and successful experience in the development and co... |
| |
|
|
|
Nothing on this website constitutes or is intended to constitute an invitation or offer to invest or deal in the securities of Intermune.
Except for the historical information contained herein, this website contains certain forward-looking statements that involve risks and uncertainties. You can identify those statements by the fact that they contain words such as "anticipate," "believe," "estimate," "expect," "potential," "intend," "project," or other terms of similar meaning. InterMune’s actual results may differ materially from those described in the forward-looking statements. All forward-looking statements and other information included in this website are based on information available to InterMune as of August 1, 2010, and InterMune assumes no obligation to update any such forward-looking statements or information. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" and the other risks and factors discussed in InterMune’s most recent Form 10-K and other periodic filings (i.e., 8-K and 10-Q) filed with the Securities and Exchange Commission. The SEC’s website is http://www/sec/gov, and our filings are contained in the SEC’s Edgar archives. Please see the Terms and Conditions of Access and Use section of this website for a listing of InterMune’s "Risk Factors," which are discussed in the periodic filings filed with the SEC.
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
Summary of Product Characteristics (SmPC) for Esbriet® (pirfenidone)